Residency · Residency · Psychiatry

Transcranial Magnetic Stimulation and Neuromodulation

Transcranial Magnetic Stimulation (TMS)

Mechanism of Action

A coil placed against the scalp generates rapidly changing magnetic fields that penetrate the skull. These magnetic fields induce small electrical currents in the underlying cortical tissue. Stimulation modulates neuronal activity in targeted brain regions and their connected circuits. High-frequency rTMS (>=5 Hz): generally excitatory (increases cortical excitability) Low-frequency rTMS (<=1 Hz): generally inhibitory (decreases cortical excitability) Therapeutic effects are thought to arise from long-term potentiation (LTP) or long-term depression (LTD) of synaptic connections, downstream neurotransmitter changes, and network-level normalization.

Standard rTMS Protocol for Depression

Target: left dorsolateral prefrontal cortex (DLPFC) -- a region consistently hypoactive in depression. Frequency: 10 Hz (high-frequency excitatory stimulation) Intensity: 120% of resting motor threshold (RMT) Sessions: typically 20-30 treatments over 4-6 weeks (5 days/week) Duration per session: approximately 20-40 minutes. FDA-cleared for treatment-resistant depression (TRD) since 2008.

Theta-Burst Stimulation (TBS)

Modified rTMS protocol delivering bursts of 3 pulses at 50 Hz repeated at 5 Hz (theta rhythm) Intermittent TBS (iTBS): applied to left DLPFC; excitatory; shown to be non-inferior to standard 10 Hz rTMS in the THREE-D trial (Blumberger et al. 2018) Major advantage: treatment time is approximately 3 minutes vs. 20-40 minutes for standard rTMS. FDA-cleared for depression in 2018. Has significantly improved patient access and clinic throughput.

Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT)

Intensive iTBS protocol delivering multiple sessions per day over 5 days (total ~50 sessions) Uses functional MRI-guided targeting of the specific DLPFC subregion with strongest anticorrelation to the subgenual anterior cingulate cortex. Open-label and sham-controlled trials showed ~80% remission rates in TRD. FDA-cleared in 2022 under the brand name BrainsWay SAINT protocol. Represents a paradigm shift: treatment compressed from 6 weeks to 5 days.

Efficacy Data

Standard rTMS: response rates ~50-60%, remission rates ~30-35% in TRD. Non-inferior to antidepressant medication in some comparisons. THREE-D trial: iTBS non-inferior to standard rTMS (response rate ~49% for both) SAINT protocol: remission rates up to 79% in initial studies (requires replication in larger samples) Effect sizes generally smaller than ECT; TMS is typically tried before ECT in treatment algorithms.

Side Effects

Headache: most common (~30%); typically mild and transient. Scalp discomfort: at the stimulation site; improves over sessions. Seizure risk: very low (<0.1%); screen for seizure risk factors. No systemic side effects (no anesthesia, no cognitive impairment, no weight gain) No memory effects -- major advantage over ECT. Contraindications: ferromagnetic implants in or near the head, cochlear implants, implanted stimulators.

Other Neuromodulation Modalities

Vagus Nerve Stimulation (VNS)

Surgically implanted pulse generator stimulates the left vagus nerve. FDA-approved for treatment-resistant depression (2005) and epilepsy. Mechanism: vagal afferents project to nucleus tractus solitarius, then to locus coeruleus and raphe nuclei -- modulates norepinephrine and serotonin. Response develops slowly (months); best evidence for long-term benefit. Rarely used due to surgical requirement, delayed onset, and modest acute efficacy.

Transcranial Direct Current Stimulation (tDCS)

Non-invasive; delivers weak constant electrical current (1-2 mA) via scalp electrodes. Modulates cortical excitability: anodal stimulation is excitatory, cathodal is inhibitory. No FDA clearance for depression; used primarily in research settings. Advantages: inexpensive, portable, minimal side effects (skin irritation, tingling) Evidence base: meta-analyses show modest antidepressant effects; effect sizes smaller than rTMS. Home-based tDCS protocols are under investigation.

Deep Brain Stimulation (DBS)

Neurosurgical implantation of electrodes in deep brain structures. Targets investigated for depression: subcallosal cingulate (Brodmann area 25), ventral capsule/ventral striatum, medial forebrain bundle. Experimental for depression; not FDA-approved for this indication. Small studies show promising results in highly treatment-resistant cases. Reserved for the most severe, refractory cases due to surgical risks.

Magnetic Seizure Therapy (MST)

Uses high-dose TMS to intentionally induce a seizure (similar to ECT but with more focal stimulation) Theoretical advantage: seizure is more focal, potentially less cognitive impairment than ECT. Still experimental; limited clinical trials. May eventually bridge the gap between TMS efficacy and ECT efficacy.

Patient Selection

Best Candidates for TMS

Treatment-resistant depression (failed 1-2 adequate antidepressant trials) Patients who cannot tolerate medication side effects. Patients who decline or are not candidates for ECT. Patients concerned about cognitive side effects of ECT. May be less effective in more severely treatment-resistant cases (failed 4+ trials)

TMS vs. ECT

ECT has higher efficacy (especially for severe, psychotic, or acutely suicidal depression) TMS has no cognitive side effects, no anesthesia requirement, no recovery time. TMS is outpatient and does not require a driver. ECT remains the gold standard for the most severe and treatment-resistant cases. TMS is typically tried before ECT in stepped-care models.

<image> A diagram showing the mechanism of TMS. Illustrate the figure-8 coil placed against the scalp, the magnetic field lines penetrating the skull, and the induced electrical currents in the underlying cortical tissue at the left DLPFC. Include an inset showing the neural effects: high-frequency stimulation increasing cortical excitability through LTP-like mechanisms. Show the target circuit: DLPFC to subgenual anterior cingulate cortex anticorrelation. Include a comparison panel showing standard rTMS pulse train vs. theta-burst stimulation pattern. Neuroscience illustration style. </image>

<image> A comparison table infographic of neuromodulation modalities for depression. Columns: TMS (standard rTMS), TMS (iTBS/SAINT), ECT, VNS, tDCS, DBS. Rows: mechanism, invasiveness, anesthesia required, treatment duration, sessions needed, response rate, remission rate, cognitive side effects, FDA approval status, typical patient population. Use icons and color coding for quick visual comparison. Clean medical reference format. </image>

<image> A treatment stepped-care algorithm showing where neuromodulation fits in the depression treatment sequence. Start with first-line pharmacotherapy/psychotherapy, then optimization/augmentation, then TMS (standard or accelerated), then ECT, then VNS or experimental approaches (DBS). Show patient flow with estimated response rates at each step and clinical decision points for moving to the next level. Include criteria for each level. Flowchart format with color-coded tiers. </image>

Clinical Pearls

TMS is a non-invasive, well-tolerated treatment with no cognitive side effects -- this makes it an attractive option before escalating to ECT. Theta-burst stimulation (iTBS) reduced session time from 40 minutes to 3 minutes with equivalent efficacy -- a game-changer for patient access. The SAINT accelerated protocol (5-day intensive iTBS) showed remarkably high remission rates but requires functional MRI-guided targeting and further replication. TMS is not effective for acute suicidality or psychiatric emergencies -- ECT remains the treatment of choice in these situations. Insurance coverage for TMS has expanded significantly; most plans now cover it for TRD after documented failure of adequate antidepressant trials. Medications that raise seizure threshold (benzodiazepines, anticonvulsants) may reduce TMS efficacy -- consider tapering if clinically safe. The left DLPFC is the standard target, but the specific subregion matters -- fMRI-guided targeting may improve outcomes in future practice.

References

• O'Reardon JP, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208-1216.
• Blumberger DM, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391(10131):1683-1692.
• Cole EJ, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for treatment-resistant depression. Am J Psychiatry. 2020;177(8):716-726.
• Brunoni AR, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data. Br J Psychiatry. 2016;208(6):522-531.
• Holtzheimer PE, Mayberg HS. Deep brain stimulation for psychiatric disorders. Annu Rev Neurosci. 2011;34:289-307.

Read this lecture as Markdown